Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADXSNYSE:AGENASDAQ:BLCMNASDAQ:PULMOTCMKTS:QBIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.57$0.71$0.50▼$1.95$6.15M1.6221,633 shs2,462 shsAGEAgeX Therapeutics$3.23$11.07▼$35.71$11.99M1.183,849 shs3,700 shsBLCMBellicum Pharmaceuticals$0.07-6.6%$0.08$0.06▼$1.31$727K1.3922,874 shs6,000 shsPULMPulmatrix$1.99+1.5%$1.85$1.55▼$3.14$7.26M0.9218,178 shs11,844 shsQBIOQ BioMed$0.00$0.00$0.00▼$0.02$29K1.72538 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals-11.70%-14.66%-8.39%-7.17%-54.03%AGEAgeX Therapeutics0.00%0.00%-23.61%+4,340.00%+2,916.30%BLCMBellicum Pharmaceuticals0.00%0.00%0.00%-29.13%-82.11%PULMPulmatrix-6.70%-7.14%+20.37%+10.17%-37.10%QBIOQ BioMed+100.00%+100.00%0.00%-66.67%-98.57%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAGEAgeX TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APULMPulmatrix0.9418 of 5 stars3.53.00.00.00.00.00.6QBIOQ BioMedN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals2.00HoldN/AN/AAGEAgeX TherapeuticsN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/APULMPulmatrix3.00Buy$10.00402.59% UpsideQBIOQ BioMedN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M1.90N/AN/A($0.61) per share-0.94AGEAgeX Therapeutics$140K0.00N/AN/A($16.07) per share0.00BLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33PULMPulmatrix$7.30M0.99N/AN/A$4.93 per share0.40QBIOQ BioMed$280K0.10N/AN/A($0.11) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala PharmaceuticalsN/A-$7.98N/A∞N/AN/A-2,798.92%-195.41%5/21/2024 (Estimated)AGEAgeX Therapeutics-$14.80M-$13.03N/AN/AN/A-10,424.65%N/A-120.90%5/13/2024 (Estimated)BLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/APULMPulmatrix-$14.12M-$3.86N/A∞N/A-193.49%-63.94%-40.88%5/10/2024 (Estimated)QBIOQ BioMed-$2.05M-$0.03N/A∞N/AN/AN/AN/A5/26/2024 (Estimated)Latest QBIO, AGE, PULM, ADXS, and BLCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023PULMPulmatrixN/A-$0.57-$0.57-$0.57N/A$2.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AAGEAgeX TherapeuticsN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/A0.530.53AGEAgeX TherapeuticsN/A0.130.36BLCMBellicum PharmaceuticalsN/A3.043.04PULMPulmatrixN/A5.335.33QBIOQ BioMedN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%AGEAgeX Therapeutics12.50%BLCMBellicum Pharmaceuticals4.93%PULMPulmatrix11.84%QBIOQ BioMedN/AInsider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%AGEAgeX Therapeutics6.50%BLCMBellicum Pharmaceuticals10.30%PULMPulmatrix3.61%QBIOQ BioMed28.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala PharmaceuticalsN/A10.75 million10.68 millionNot OptionableAGEAgeX Therapeutics51.08 million1.01 millionNot OptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionablePULMPulmatrix283.65 million3.52 millionNot OptionableQBIOQ BioMed3145.10 million104.18 millionNot OptionableQBIO, AGE, PULM, ADXS, and BLCM HeadlinesSourceHeadlineE&Q Master Cordless Gutta Percha Obturator from Meta BioMednews-medical.net - March 24 at 4:19 AMClearside Biomedical Q4 2023 Earnings Previewmsn.com - March 11 at 7:34 PMQ BioMed Stock (OTC:QBIO) Dividends: History, Yield and Datesbenzinga.com - February 24 at 3:23 AMBiogen Inc. (BIIB) Lags Q4 Earnings and Revenue Estimatesmsn.com - February 13 at 1:26 PMBioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growthmsn.com - January 28 at 11:09 PMQ BioMed Inc QBIOmorningstar.com - November 16 at 1:23 PMBiomedical Sciences PhD Programuwyo.edu - November 13 at 2:32 PMQ&A: How generative AI could help accelerate biomedical researchphys.org - November 6 at 8:46 AMQBIO Q BioMed Inc.seekingalpha.com - August 18 at 4:51 AMQ BioMed’s chemotherapeutic Uttroside B gets US patent and notice of allowance in Europepharmabiz.com - April 17 at 9:36 AMQ BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder valueproactiveinvestors.com - April 14 at 10:53 AMQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europefinance.yahoo.com - April 14 at 10:53 AMQ BioMed Stock (OTC:QBIO), Quotes and News Summarybenzinga.com - March 3 at 4:23 PMQ BioMed gets notice of allowable US patent for liver cancer treatment Uttroside Bproactiveinvestors.com - February 10 at 3:27 PMQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Officefinance.yahoo.com - February 10 at 8:27 AMShort Volatility Alert: Q Biomed Incbenzinga.com - January 12 at 2:36 PMQ BioMed Inc. (QBIO)finance.yahoo.com - January 1 at 5:15 PMQ BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Researchproactiveinvestors.com - November 14 at 2:22 PMQ BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.finance.yahoo.com - November 14 at 9:20 AMQ BIOMED PROVIDES SHAREHOLDER UPDATEprnewswire.com - October 11 at 8:38 AMQ Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatmentproactiveinvestors.com - September 27 at 1:02 PMQ BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKERfinance.yahoo.com - September 27 at 1:02 PMTraders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.finance.yahoo.com - August 25 at 10:16 AMWhat to Expect at BIOMEDevice Bostonmddionline.com - August 10 at 3:59 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s Portfolio5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come2 Data Storage Device Stocks Thriving From the AI BoomApril 2, 2024 7:25 AMView 2 Data Storage Device Stocks Thriving From the AI BoomMicron Technology Results Proves AI is Driving Storage DemandMarch 26, 2024 7:35 AMView Micron Technology Results Proves AI is Driving Storage DemandYou Can Follow BlackRock’s Market View for Your MoneyApril 12, 2024 10:00 AMView You Can Follow BlackRock’s Market View for Your MoneyAll Headlines Company DescriptionsAyala PharmaceuticalsNASDAQ:ADXSAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.AgeX TherapeuticsNYSE:AGEAgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.Bellicum PharmaceuticalsNASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.PulmatrixNASDAQ:PULMPulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.Q BioMedOTCMKTS:QBIOQ BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.